Terrell Gibbs

List of Publications by Year
in descending order

22 papers	1,760 citations	361413 20 h-index	677142 22 g-index
22 all docs	22 docs citations	22 times ranked	1472 citing authors

#	Article	IF	Citations
1	Sulfated and unsulfated steroids modulate Î³-aminobutyric acidA receptor function through distinct sites. Brain Research, 1999, 830, 72-87.	2.2	316
2	17Î²-Estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors. Brain Research, 1997, 761, 338-341.	2.2	264
3	Ethanol potentiates GABA- and glycine-induced chloride currents in chick spinal cord neurons. Brain Research, 1988, 455, 377-380.	2.2	180
4	Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids. British Journal of Pharmacology, 2002, 135, 901-909.	5.4	156
5	Selective anxiolysis produced by ocinaplon, a GABAA receptor modulator. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7380-7385.	7.1	119
6	Sulfated steroids as endogenous neuromodulators. Pharmacology Biochemistry and Behavior, 2006, 84, 555-567.	2.9	101
7	Neurosteroid modulation of recombinant ionotropic glutamate receptors. Brain Research, 1998, 803, 153-160.	2.2	78
8	Benzodiazepine modulation of partial agonist efficacy and spontaneously active GABAA receptors supports an allosteric model of modulation. British Journal of Pharmacology, 2005, 145, 894-906.	5.4	69
9	Î³-Aminobutyric acidA receptor regulation: heterologous uncoupling of modulatory site interactions induced by chronic steroid, barbiturate, benzodiazepine, or GABA treatment in culture. Brain Research, 1996, 707, 100-109.	2.2	66
10	Dual activation of GABAA and glycine receptors by Î²-alanine: inverse modulation by progesterone and 5Î±-pregnan-3Î±-ol-20-one. European Journal of Pharmacology, 1993, 246, 239-246.	2.6	63
11	Pregnenolone sulfate exacerbates NMDA-induced death of hippocampal neurons. Brain Research, 1998, 803, 129-136.	2.2	50
12	Distinct signal transduction pathways for GABA-induced GABAA receptor down-regulation and uncoupling in neuronal culture: a role for voltage-gated calcium channels. Journal of Neurochemistry, 2001, 78, 1114-1126.	3.9	41
13	Turnover and Down-Regulation of GABAA Receptor Î±1, Î²2S, and Î³1 Subunit mRNAs by Neurons in Culture. Journal of Neurochemistry, 2000, 74, 1041-1048.	3.9	40
14	The Anxioselective Agent 7-(2-Chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) Is More Efficacious Than Diazepam at Enhancing GABA-Gated Currents at Î±1 Subunit-Containing GABAA Receptors. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1244-1252.	2.5	39
15	The Neuroactive Steroid Pregnenolone Sulfate Stimulates Trafficking of FunctionalN-Methyl D-Aspartate Receptors to the Cell Surface via a Noncanonical, G Protein, and Ca²⁺-Dependent Mechanism. Molecular Pharmacology, 2013, 84, 261-274.	2.3	33
16	Pregnenolone sulfate induces NMDA receptor dependent release of dopamine from synaptic terminals in the striatum. Journal of Neurochemistry, 2008, 107, 510-521.	3.9	25
17	Docking of 1,4-Benzodiazepines in the Î±₁/Î³₂GABA_AReceptor Modulator Site. Molecular Pharmacology, 2009, 76, 440-450.	2.3	25
18	A steroid modulatory domain in NR2A collaborates with NR1 exonâ€5 to control NMDAR modulation by pregnenolone sulfate and protons. Journal of Neurochemistry, 2011, 119, 486-496.	3.9	25

#	Article	IF	Citations
19	Molecular and cellular mechanisms of GABA/benzodiazepine-receptor regulation: Electrophysiological and biochemical studies. Neurochemical Research, 1990, 15, 175-191.	3.3	23
20	Multiple embryonic benzodiazepine binding sites: Evidence for functionality. Life Sciences, 1983, 33, 2061-2069.	4.3	20
21	Inhibition of NMDA-induced striatal dopamine release and behavioral activation by the neuroactive steroid 3Î±-hydroxy-5Î²-pregnan-20-one hemisuccinate. Journal of Neurochemistry, 2004, 86, 92-101.	3.9	16
22	Nanomolar Concentrations of Pregnenolone Sulfate Enhance Striatal Dopamine Overflow in Vivo. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 840-845.	2.5	11